Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
Eur J Pharm Biopharm · 2020
Last updated 2026-05-28Researchers tested two methods to help the diabetes drug exenatide (a GLP-1 drug) travel through the gut by pairing it with different compounds to make it more fat-friendly. When given to rats as a pill, one version (paired with THA) worked 28% as well as an injection, while the other (paired with DOC) worked 16% as well. Neither version caused significant harm to red blood cells at tested doses.
AI summary of the abstract below.
| Journal | Eur J Pharm Biopharm, 2020 |
|---|---|
| Citations | 34 |
| Relative citation ratio | 2.48 |
| NIH percentile | 79 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
The lipophilic character of peptides can be tremendously improved by hydrophobic ion pairing (HIP) with counterions to be efficiently incorporated into lipid-based nanocarriers (NCs). Herein, HIPs of exenatide with the cationic surfactant tetraheptylammonium bromide (THA) and the anionic surfactant sodium docusate (DOC) were formed to increase its lipophilicity. These HIPs were incorporated into lipid based NCs comprising 41% Capmul MCM, 15% Captex 355, 40% Cremophor RH and 4% propylene glycol. Exenatide-THA NCs showed a log D of 2.29 and 1.92, whereas the log D of exenatide-DOC was 1.2 and -0.9 in simulated intestinal fluid and Hanks' balanced salts buffer (HBSS), respectively. No significant hemolytic activity was induced at a concentration of 0.25% (m/v) of both blank and loaded NCs. Exenatide-THA NCs and exenatide-DOC NCs showed a 10-fold and 3-fold enhancement in intestinal apparent membrane permeability compared to free exenatide, respectively. Furthermore, orally administered exenatide-THA and exenatide-DOC NCs in healthy rats resulted in a relative bioavailability of 27.96 ± 5.24% and 16.29 ± 6.63%, respectively, confirming the comparatively higher potential of the cationic surfactant over the anionic surfactant. Findings of this work highlight the potential of the type of counterion used for HIP as key to successful design of lipid-based NCs for oral exenatide delivery.
Verbatim abstract via PubMed 32371152 ↗